Suppr超能文献

氧烯洛尔在心律失常治疗与预防中的应用

[Oxprenolol in the treatment and prevention of cardiac arrhythmias].

作者信息

Martinoli E, Medugno G, Crepaldi L, Scardi S, Camerini F

出版信息

Minerva Med. 1975 Oct 13;66(68):3566-73.

PMID:52854
Abstract

Authors have analyzed the antiarrhythmic effect of oxprenolol, a beta blocking agent, in the treatment of various types of arrhythmias and in the prophylaxis of recurrences of auricular flutter and fibrillation. The results obtained in a group of 68 cases of different arrhythmias may be summarized in the following way: a) the drug efficiently reduces the ventricular rate in sinus tachycardia and in atrial flutter and fibrillation with high ventricular rate, even if resistant to treatment with digitalis; b) in patients with asynchronous pacemaker oxprenolol leads to disappearance or an important reduction of competitive rhythms; c) in supraventricular paroxysmal tachycardias the results are positive in the majority of cases (while on the contrary in 2 cases of ventricular tachycardias the drug was not effective). A group of 116 cases with auricular flutter or fibrillation (in which sinus rhythm had been restored with quinidine or cardioversion has been analyzed to study the prophylactic activity of oxprenolol in these arrhythmias. The cases have been divided at random into two groups and have been treated with quinidine (g 0.80 p.d.) or with an association of oxprenolol (mg 60 p.d.) and quinidine (g 0,60 p.d.). The observation period varied from a minimum of 1 month to a maximum of 3 years and 3 months. The curves showing the percentage of persistance of sinus rhythm in the two groups were very similar and after 3 years and 3 months 100% of patients observed presented a recurrence of arrhythmias.

摘要

作者分析了β受体阻滞剂氧烯洛尔在治疗各类心律失常以及预防心房扑动和颤动复发方面的抗心律失常作用。在一组68例不同类型心律失常患者中所获结果可总结如下:a) 该药能有效降低窦性心动过速以及心室率较高的心房扑动和颤动时的心室率,即便对洋地黄治疗耐药;b) 对于异步起搏器患者,氧烯洛尔可使竞争性节律消失或显著降低;c) 在室上性阵发性心动过速患者中,多数情况下结果呈阳性(相反,在2例室性心动过速患者中该药无效)。对一组116例心房扑动或颤动患者(已用奎尼丁恢复窦性心律或已进行心脏复律)进行了分析,以研究氧烯洛尔对这些心律失常的预防作用。这些病例被随机分为两组,分别用奎尼丁(每日0.80克)或氧烯洛尔(每日60毫克)与奎尼丁(每日0.60克)联合治疗。观察期最短为1个月,最长为3年零3个月。两组显示窦性心律持续百分比的曲线非常相似,在3年零3个月后,所有观察患者均出现心律失常复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验